Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
about
YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cellsInhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.Determinants and clinical implications of chromosomal instability in cancer.Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications.Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.Targeting the cell cycle in breast cancer: towards the next phaseIntroduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N-neopentyl
P2860
Q33821469-A1B97946-0B2D-401D-80FF-89A68633DEF5Q38429562-F86C0855-7809-438D-B1BF-3D20F99BCAE3Q47119995-B5CD4F52-37C4-4BBA-8C27-BA13B8408D9EQ48147604-DA213665-0901-4891-A1DC-EA1A30060EECQ49347721-13E7B764-DEC9-4165-9D5A-09AA56EE36A2Q49775755-1083B5EA-3701-42FD-AE24-E06F775BF984Q54111735-AA2E1665-CF61-4D32-9F12-79B33E7A4849Q57115037-DE347421-935E-4E78-BBF7-F254C1EAD5E4Q58753054-76264A1E-A6B8-492B-9CCA-E6D6C494BB7B
P2860
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Functional characterization of ...... , for the treatment of cancer.
@en
Functional characterization of ...... , for the treatment of cancer.
@nl
type
label
Functional characterization of ...... , for the treatment of cancer.
@en
Functional characterization of ...... , for the treatment of cancer.
@nl
prefLabel
Functional characterization of ...... , for the treatment of cancer.
@en
Functional characterization of ...... , for the treatment of cancer.
@nl
P2093
P2860
P356
P1476
Functional characterization of ...... , for the treatment of cancer.
@en
P2093
Graham C Fletcher
Irina Beletskaya
Jacqueline M Mason
Mark R Bray
Reza Kiarash
Richard Brokx
Richard Hodgson
P2860
P304
P356
10.1073/PNAS.1700234114
P407
P577
2017-03-07T00:00:00Z